BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33324410)

  • 1. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
    Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
    Front Immunol; 2020; 11():558143. PubMed ID: 33178187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.
    Mammadli M; Huang W; Harris R; Xiong H; Weeks S; May A; Gentile T; Henty-Ridilla J; Waickman AT; August A; Bah A; Karimi M
    iScience; 2021 Apr; 24(4):102286. PubMed ID: 33851101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
    Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
    Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
    Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
    Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
    Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation.
    Darlak KA; Wang Y; Li JM; Harris WA; Owens LM; Waller EK
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1331-9. PubMed ID: 23810844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.
    Hanash AM; Kappel LW; Yim NL; Nejat RA; Goldberg GL; Smith OM; Rao UK; Dykstra L; Na IK; Holland AM; Dudakov JA; Liu C; Murphy GF; Leonard WJ; Heller G; van den Brink MR
    Blood; 2011 Jul; 118(2):446-55. PubMed ID: 21596854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
    Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
    Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.
    Liang Y; Liu C; Djeu JY; Zhong B; Peters T; Scharffetter-Kochanek K; Anasetti C; Yu XZ
    Blood; 2008 Jan; 111(2):954-62. PubMed ID: 17928532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice.
    Kim S; Lim S; Kim B; Ritchey J; Vij K; Prior J; Marsala L; Stoner A; Gao F; Achilefu S; Cooper ML; DiPersio JF; Choi J
    Blood; 2023 Feb; 141(8):945-950. PubMed ID: 36477272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.